Search
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. … It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.
Categories: Angiotensin 2 Receptor Blocker, Angiotensin Receptor AntagonistsPoloxamer 188
go.drugbank.com/drugs/DB11333ApprovedDue to its sufactant properties, P188 may also be found in over-the-counter (OTC) products such as toothpaste, laxatives and mouthwash, and used in various cosmetic, industrial and pharmaceutical applications
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalHowever, its use for the treatment of acute ischemic stroke (AIS) has increased over the years.
Methimazole
go.drugbank.com/drugs/DB00763ApprovedInvestigational[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred
Buspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalBelonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates
Categories: Dopamine D2 Receptor AntagonistsGavestinel
go.drugbank.com/drugs/DB06741ExperimentalGavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo. … Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalIt has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55. … JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.
IR208
go.drugbank.com/drugs/DB05106InvestigationalIt contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.